Swiss dermatology company Galderma Group AG’s flagship skin care brands Cetaphil and Alastin drove net sales of its Dermatological Skincare division up 10.6% year-on-year at constant currency rates in the first nine months to $990m. Cetaphil growth was “particularly strong” in non-US markets, more than offsetting lower consumer consumption in the US, while Alastin continued its US growth across channels, said the firm, with US headquarters in Dallas. Cetaphil is marketed in 90 countries. In the quarter, the firm invested behind Cetaphil’s growth “with a re-energized brand, focused retailer execution and a digital-first activation,” Galderma said. “This included placement in Walmart in the US with a multi-channel activation.” The company also launched Cetaphil Gentle Exfoliating line “to provide gentle chemical exfoliation that is suitable for daily use, even on the most sensitive skin.”
Cosmetics Industry Q3: Cetaphil Investments Drive Galderma Derm Division; Inflation Impacting Direct-To-Consumer Sales; More
Galderma Group AG’s investments in Cetaphil launch, ‘re-energizing’ of brand pay off with sales of the dermatology unit up 10.6% in the third quarter. Separately, Spanish beauty company Puig reports its Fragrance and Fashion business grew 11.1% and its makeup division advanced 7.3% in the quarter, while data insights company Consumer Edge identifies slowdown in direct-to-consumer beauty sales.
More from Earnings
Coty Inc. reports fiscal second quarter sales slipped 3% on a reported basis to $1.67bn, reflecting further slowing of the mass beauty market, particularly color cosmetics.
L’Oréal Groupe expects total sales in 2025 to beat 4%-4.5% growth anticipated for the overall beauty market, with US population growth, planned innovations boding well across its beauty businesses.
Cincinnati-based P&G reports its antiperspirants/deodorants business is a ‘pocket of strength,’ growing 11% in the US in the fiscal second quarter and helping lift overall beauty sales as skin care stumbles.
New York-based International Flavors & Fragrances, Inc.’s Scent division is undertaking R&D in natural, synthetic chemistry and biotech molecules, says CEO Erik Fyrwald during a third quarter earnings presentation 6 November.
More from HBW Insight
Vitawell seeking to empower consumers left confused by the vast array of dietary supplements available to them in the UK.
Tariffs on imports from China and look at eliminating self-affirmed GRAS pathway introduced under Trump while DoJ Consumer Protection Branch also continues supplement sector priorities enduring across administrations.
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.